These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 10553211)

  • 21. Clinical utility of the Food and Drug Administration Electrocardiogram Warehouse: a paradigm for the critical pathway initiative.
    Cabell CH; Noto TC; Krucoff MW
    J Electrocardiol; 2005 Oct; 38(4 Suppl):175-9. PubMed ID: 16226096
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ASTM lights the way for tissue engineered medical products standards: jump start for combination medical products that restore biological function of human tissues.
    Picciolo GL; Stocum DL
    Stand News; 2001 Jan; 29(1):30-5. PubMed ID: 11833591
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Diagnostic kits in parasitology: which controls?].
    Rossi P
    Parassitologia; 2004 Jun; 46(1-2):145-9. PubMed ID: 15305705
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Considerations for tissue-engineered and regenerative medicine product development prior to clinical trials in the United States.
    Lee MH; Arcidiacono JA; Bilek AM; Wille JJ; Hamill CA; Wonnacott KM; Wells MA; Oh SS
    Tissue Eng Part B Rev; 2010 Feb; 16(1):41-54. PubMed ID: 19728784
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Naturally occurring asbestos: a recurring public policy challenge.
    Lee RJ; Strohmeier BR; Bunker KL; Van Orden DR
    J Hazard Mater; 2008 May; 153(1-2):1-21. PubMed ID: 18180100
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Will regulation be the death of cell therapy in the United States?
    Gastineau DA
    Bone Marrow Transplant; 2004 Apr; 33(8):777-80. PubMed ID: 14968138
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Managing the expanded use of biologics across therapeutic areas: an example from b-cell targeted therapies.
    Cohen M; Morrow T; Penna P
    Am J Manag Care; 2006 Mar; 12(2 Suppl):S24-37; quiz S38. PubMed ID: 16551202
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Displaced agendas: current regulatory strategies for germline gene therapy.
    Marden E; Nelkin D
    McGill Law J; 2000 May; 45(2):461-81. PubMed ID: 12688283
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Separating predictive genetic testing from snake oil: regulation, liabilities, and lost opportunities.
    Malinowski MJ
    Jurimetrics; 2000; 41(1):23-52. PubMed ID: 15744897
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How will we regulate genetic enhancement?
    Mehlman MJ
    Wake Forest Law Rev; 1999; 34(3):671-714. PubMed ID: 12664908
    [TBL] [Abstract][Full Text] [Related]  

  • 31. US regulatory system for genetically modified [genetically modified organism (GMO), rDNA or transgenic] crop cultivars.
    McHughen A; Smyth S
    Plant Biotechnol J; 2008 Jan; 6(1):2-12. PubMed ID: 17956539
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Policy developments in regulatory approval.
    Temple R
    Stat Med; 2002 Oct; 21(19):2939-48. PubMed ID: 12325110
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of Food and Drug Administration 510(k) notifications in patent litigation.
    Tolomeo DE
    Food Drug Law J; 2004; 59(4):465-77. PubMed ID: 15875346
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Marketing dietary supplements in the United States: a review of the requirements for new dietary ingredients.
    Noonan C; Patrick Noonan W
    Toxicology; 2006 Apr; 221(1):4-8. PubMed ID: 16497425
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Food and Drug Administration and atrial defibrillation devices.
    Chen L; Keane AT; Every NR
    Am J Manag Care; 1999 Jul; 5(7):899-909. PubMed ID: 10557410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulations for in vivo radiopharmaceuticals used for diagnosis and monitoring. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 1999 May; 64(94):26657-70. PubMed ID: 10558516
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulatory considerations for determining postmarketing study commitments.
    Meyer RJ
    Clin Pharmacol Ther; 2007 Aug; 82(2):228-30. PubMed ID: 17538552
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human cells, tissues, and cellular and tissue-based products; establishment registration and listing. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2001 Jan; 66(13):5447-69. PubMed ID: 11503777
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FDA regulation of stem cell-based products.
    Fink DW
    Science; 2009 Jun; 324(5935):1662-3. PubMed ID: 19556496
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gastroenterology-urology devices; classification of tissue culture media for human ex vivo tissue and cell culture processing applications. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2001 May; 66(95):27023-5. PubMed ID: 11721690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.